Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02820961 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer
A Phase 1 study, sponsored by Syndax Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT02820961 is a Phase 1 study that has completed, run by Syndax Pharmaceuticals. The registered enrollment target is 61 participants.
The verdict
NCT02820961, a Phase 1 study, has completed, sponsored by Syndax Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of exemestane on the pharmacokinetics (PK) of entinostat and to determine the effect of entinostat on the PK of exemestane in patients with locally recurrent or metastatic estrogen receptor positive (ER+) breast cancer. Additionally, this study will evaluate the safety and tolerability of entinostat in combination with exemestane, and assess the effectiveness of entinostat in combination with exemestane in terms of best overall response and overall survival.
Interventions
- DRUG exemestane
- DRUG entinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2016-06-29 |
| Est. Completion | 2021-07-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02820961
The ClinicalTrials.gov registry entry for NCT02820961 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which exemestane is the first listed.
NCT02820961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02820961 about?
NCT02820961 is a clinical study titled "Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer". The purpose of this study is to determine the effect of exemestane on the pharmacokinetics (PK) of entinostat and to determine the effect of entinostat on the PK of exemestane in patients with locally recurrent or metastatic estrogen receptor positive (ER+) breast cancer. Additionally, this study wi...
What is the current status of trial NCT02820961?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2016-06-29. Estimated completion is 2021-07-12.
What interventions are being tested in trial NCT02820961?
The interventions under investigation include: exemestane (DRUG), entinostat (DRUG).
Who is sponsoring clinical trial NCT02820961?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.